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Abstract
The neurofilament light subunit (NF-L) binds to myosin Va (Myo Va) in neurons but the sites of interaction and functional
significance are not clear. We show by deletion analysis that motor domain of Myo Va binds to the NF-L rod domain that
forms the NF backbone. Loss of NF-L and Myo Va binding from axons significantly reduces the axonal content of ER, and
redistributes ER to the periphery of axon. Our data are consistent with a novel function for NFs as a scaffold in axons for
maintaining the content and proper distribution of vesicular organelles, mediated in part by Myo Va. Based on observations
that the Myo Va motor domain binds to intermediate filament (IF) proteins of several classes, Myo Va interactions with IFs
may serve similar roles in organizing organelle topography in different cell types.
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Introduction
Cellular transport is mediated by molecular motor proteins
including kinesin, dynein/dynactin complex, and myosins. Kinesin
and dynein/dynactin motors are powered by microtubule-
dependent mechanisms, whereas myosin motor proteins move
their cargoes by a ‘‘hand-over hand’’ mechanism along actin
filaments [1]. The major proposed cargoes of Myo Va are
membranous organelles, including melanosomes, synaptic vesicles,
endosomes and mitochondria [2,3]. Within the super family of
myosin motors, myosin V is highly enriched in brain, and exists as
3 different isoforms in vertebrates: Myo Va, Vb and Vc [4]. Myo
Va, which is highly conserved from yeast to mammals [5,6], is
composed of an amino terminal head domain containing an
ATPase and an actin binding domain, a small neck containing
calmodulin-binding IQ motifs, and a tail containing coiled-coil
dimerization domains interrupted by noncoiled-coil regions and a
globular domain involved in cargo binding [7,8,9]. The Myo Va
motor complex includes two heavy chains, 12 calmodulins that
bind to the neck region, and a dynein light chain 2 [10], and
calmodulin kinase II, both of which bind to the tail region [11,12].
Myo Va in neurons is believed to transport synaptic vesicles,
ER, mitochondria and membrane bound vesicles along axons and
within synaptic terminals, and to facilitate the accumulation of
mRNA/protein complexes in dendritic spines [13]. Its special
importance in the nervous system is suggested by the fact that Myo
Va mutations cause a neurodevelopmental disorder, Griscelli
Syndrome type 1, which is characterized by mental retardation,
seizures and death early in life [14]. Myo Va mutations in mice
cause an analogous syndrome, the dilute-lethal [dl] phenotype [6].
More recently, Myo Va has been shown to bind to neurofilaments
(NFs),and other intermediate filament (IF) proteins from different cell
types [15,16]. NFs in the CNS are assembled from four subunits, the
neurofilament light (NF-L), middle (NF-M), heavy (NF-H) subunits,
and a-internexin [17]. NF networks are extensively cross-linked with
actin filaments and microtubules [18,19]. Myo Va binds to the NF-L
subunit of NFs, which is essential for maintaining normal Myo Va
levelswhile, loss of Myo Va leads to altered NF organization in axons
[16]. However, the biological significance of the binding between
Myo Va and NF-L is not clear.
In this study, we demonstrate that NF-L, rod domain, binds
directly the N-terminal motor domain of Myo Va. It is well-
established that the Myo Va cargo domain binds vesicular
organelles (7–9), and our morphological and fractionation data
(this study) demonstrate association among vesicular organelles,
Myo Va, and NF-L. We showed that loss of NF-L and Myo Va
leads to reduction in axonal levels of organelle markers and
increased peripheral distribution of ER toward the actin-rich
subaxolemmal region. Collectively, our studies provide evidence
that Myo Va binding to NF-L modulates the distribution of
vesicular organelles in axons. The binding of various IFs to the
Myo Va head domain raises the possibility that IFs may facilitate
Myo Va-mediated distribution of organelles along multiple IF
systems in different cell types.
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Ethics Statement
All the animal protocols described in the paper were approved
by the Nathan Kline Institute Animal Care and Use Committee
Protocol AP2005-155.
Mutant mice
NF-L null mice are provided by Dr. Jean-Pierre Julien, Laval
University, Canada [20]; Myo Va mutants (DL20J breeders [21])
were fed with high fat (9%) diet (Purina, St. Louis, MO), and are a
kind gift of Dr. Nancy A. Jenkins (NCI, MD). NF-L null mice are
in mixed 129/BL6/J while DL20J are in pure BL6/J genetic
background. Animals are maintained at 12 hr light and dark
cycles. Neuronal tissues (spinal cord, sciatic nerve, brain, and optic
nerves) were collected from cervical dislocated mice.
Constructs of MBP and His tagged Myo Va proteins
Myo Va head, neck and tail regions tagged with maltose
binding protein (MBP) were described previously [11]. A Myo Va
head construct encoding amino acids 41–505 was generated with
Xho I -Eco RI [6]. This construct was digested with Xho I- Bst BI
to generate 41–326 and Bst BI-Eco RI to generate 327–505
constructs [6]. To generate a neck region construct (amino acids
654–1402), Sal I was used. A construct encoding amino acids 640–
881 was generated with Bmg BI- Psp XI from a Myo Va cDNA
[11]; the 718–799 construct was PCR amplified with primer sets of
59-GCA TGA ATT CCA GAA AGA TGT CCT TAG T-39 and
59-GCA AGC TTC TGA ATG GTG ATG GCA GC-39; a 800–
881 construct was PCR amplified with primer sets of 59-GCA
TGA ATT CAG ATA TGT CAG AGG GCA C-39 and 59-GCA
AGC TTT CGA GCC AGC CAG CCT CTC-39 and chicken
Myo Va as a template [11]. All of the fragments were gel purified
and cloned in-frame with an MBP sequence into a pMAL vector
(New England Biolabs, MA) to tag the proteins with MBP. Myo
Va tail regions spanning amino acids 952–1852 were digested with
Eco RI, 952–1256 and 1257–1852 were generated by digesting
952–1852 with Sac I and Eco RI, and cloned into pQE vectors
(Qiagen, Valencia, CA) to tag the proteins with hexa-His peptide
(See Fig. S1A-E for protein expression).
Construction of Myc-tagged NF-L domain deletions
A full-length NF-L-myc tagged construct [16] was digested with
Nde I- Acc 65 I (1-369 amino acids), and Nde I- Bgl II (1–243) was
end filled and ligated in frame with the C-terminal Myc-tagged
pET11a expression construct (Novagen, Gibbstown, NJ). Full-
length NF-L construct was also digested with Nde I-Pvu II (1–93
amino acids), and Pvu II-Bgl II (94–243), end-filled and ligated in
frame with the N-terminal Myc-tagged pET11a expression vector
(for protein expression, see Fig. S1G).
Preparation of bacterial lysates and purification of Myo
Va constructs
MBP tagged-Myo Va constructs and NF-L-Myc tagged
constructs were transformed into the BL21-DE bacterial strain.
Cultures were grown to 0.6 OD and induced with IPTG to
overexpress proteins for 1 hr at 37uC. Cultures were centrifuged
and the pellets were suspended in a 50 mM sodium phosphate
buffer pH 7.0 containing 1% SDS and 1 mM EDTA. Cells were
subjected to freeze-thaw in a dry ice-ethanol bath (3 times),
sonicated and centrifuged. Clear supernatants were assayed for
protein, immunoblotted with either MBP or NF-L (NR-4 or 21.4)
or Myc (9E10) antibodies. Some of the MBP-Myo Va constructs
were affinity purified on amylose columns (New England Bio Labs,
MA). Bacterial cells after induction were lysed in a column buffer
containing 20 mM Tris-HCl, pH 7.4, 200 mM NaCl and 1 mM
EDTA by freeze thawing in a dry ice ethanol bath (3X). The
lysates were centrifuged and the pellets were dissolved in the
column buffer (20 mM Tris-HCl, pH 7.4, 200 mM NaCl and
1 mM EDTA) with 6M-guanidine hydrochloride, dialyzed in TBS
buffer (20 mM Tris/HCl, pH 7.4 containing 150 mM NaCl) over
night at 4uC, and centrifuged. Clear supernatants were then
loaded on a 5 ml amylose column (30 ml/hr), washed and the
proteins were eluted with 10 mM maltose in column buffer.
Purification of NF-L from mouse spinal cords
NF-L was purified from mouse spinal cord NF pellet as
described earlier [22] with modifications. Briefly, mouse spinal
cords were homogenized in a buffer (1:5 W/V) containing 20 mM
Tris-HCl, pH 6.8 with 1 mM each of EDTA, EGTA, DTT and
100 mM NaCl, 0.2 mM PMSF, leupeptin (5 mg/ml) and 1%
Triton X-100, and centrifuged at 20,000 g for 45 min. The pellet
(P1) that has NFs was homogenized in the same buffer with 1 M
sucrose, and centrifuged as indicated above for 30 min to obtain
NF enriched pellet (P2). This step was repeated 3 more times to
obtain NF pellet (P5) that is highly enriched in NFs. The NF pellets
were dissolved in 8 M urea and subjected to 7.5% SDS-PAGE on
17 cm gels with molecular weight markers. The gels were stained
with 0.3 M Zinc Chloride as described previously [23], the
transparent protein band of 70-kDa NF-L was cutout, washed in
0.25 M EDTA, electroeluted in 1X SDS-gel running buffer in a
dialysis bag at 20 mAmp overnight at 4uC. The electroelution was
carried out for another hr without SDS in the same buffer, eluted
protein was dialyzed overnight in a 50 mM Ammonium
bicarbonate, pH 8.0 buffer. Eluted NF-L concentration was
determined by BCA protein assay, analyzed on SDS-PAGE to
observe a single band of 70-kDa that is stained with Coomassie
Blue, immunoblotted with NR-4 and 21.4 antibodies to confirm
that the protein is NF-L (see Fig. S1F, lanes 1, 3, 5 and 7).
Preparation of Triton X-100 insoluble cytoskeletal
fractions enriched in neurofilaments
Brain, optic nerve, spinal cord, and sciatic nerves from wild type
(WT) and NF-L null mice were dissected and cytoskeletal
preparations enriched for NFs were made according to [16].
Briefly, tissues were homogenized in a cytoskeletal extraction
buffer (50 mM Tris-HCl, pH 6.8; 200 mM NaCl, 1% Triton-X-
100, 20% glycerol, and 1 mM EDTA), centrifuged, and the pellets
containing the cytoskeletal fractions were suspended in the same
buffer, sonicated, and analyzed for protein content.
Isolation of organelle-containing cytoskeletal scaffolds
from optic nerve
Optic nerves were homogenized in a buffer containing 50 mM
Tris-HCl, pH 7.4, 0.25 M sucrose, 1 mM each of EDTA, EGTA
and DTT [24], centrifuged at 7000 g for 20 min at 4uC, and
supernatants were saved. Pellets containing organelles associated
with cytoskeleton were homogenized again in the same buffer and
sonicated. Equal amounts of cytoskeletal and supernatant proteins
were immunoblotted with antibodies to cytoskeletal proteins and
organelle markers listed below.
Immunoblot analysis of bacterial and mouse extracts
Bacterially expressed Myo Va mutant proteins, and NF-L
mutant proteins, purified or cytoskeletal preparations containing
NF-L, and total tissue extracts from mouse neuronal tissues (WT,
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Proteins were fractionated on polyacrylamide gels containing SDS,
transferred to nitrocellulose membranes, blocked in 3% non-fat
dry milk, and incubated with either anti-MBP-HRP (New England
Bio Labs, MA), or other antibodies including (source in
parentheses) NF-L (NR-4), hexa-His, a, b, bIII tubulin, synapto-
physin, and actin (Sigma Chemical Co, St. Louis, MO); 21.4 [25];
Myc (9E10, Santa Cruz Biotech, CA); Myo Va [16]; calnexin
(Stressgen Bioreagents, Canada); PSD-95 (Millipore, CA); Rab-5
(Abcam, MA), and Rho B (Cell Signaling, MA). After washing, the
membranes were incubated with the corresponding HRP-
conjugated secondary antibodies and immunoreactive bands were
detected with ECL reagent (GE Healthcare, NJ). Images were
scanned, and bands were quantified with a multigauge program
(Fuji film, Japan).
Co-immunoprecipitation of NF-L and Myo Va mutant
proteins
Using purified MBP as a standard (NEB, MA), we quantified
the amount of MBP-tagged Myo Va mutant proteins for each
expressed construct on immunoblots with anti-MBP antibody.
Equal amounts of protein corresponding to each MBP-Myo Va
construct (0.5–2 mg) and purified or Myc-tagged NF-L (0.5–2 mg)
were mixed for 1 hr in 1X RIPA buffer for co-IP assays. Antibody
directed against NF-L (NR-4 or 21.4 or 9E10 for Myc tag) was
then added and the mixture was incubated for 1 hr at room
temperature (RT). Protein A/G Sepharose beads were added and
incubated for another 1 hr at RT. Immunocomplexes were
centrifuged and the precipitates were washed (3X) with high salt
solution (50 mM Tris-HCl, pH 7.4; 500 mM NaCl; 1 mM
EDTA; 0.1% NP40; 0.02% SDS; 0.02% NaN3), dissolved in
Laemmli buffer, fractionated on polyacrylamide gels along with 5–
10% of the supernatant from the IPs and the input. Gels were
transferred to nitrocellulose membranes and immunoblotted with
MBP and NF-L antibodies as indicated above. To take equimolar
concentrations of the protein, bacterial extracts containing NF-L
and MBP-tagged Myo Va proteins were fractionated on gels along
with known concentrations of BSA. The Coomassie stained gels
were scanned and protein bands of NF-L, MBP-Myo Va and BSA
were quantified using the multigauge program. To compare two
proteins based on the number of amino acids each protein has, we
calculated the molecular weight (MW) of the proteins and the MW
of the bigger protein was divided by that of the smaller protein.
The resultant value was multiplied by the amount of protein taken
for the smaller construct to obtain the equimolar concentration of
the larger protein. To achieve an excess amount of NF-L for IPs,
we took a 2–3 fold greater amount of NF-L relative to the MBP-
Myo Va constructs.
Actin activated Myo-Va-ATPase assay
Myo Va enriched from vesicles was prepared from mouse brain
as described previously [26]. Briefly, mouse brains were homog-
enized (1:4 W/V) at 4uC in 40 mM HEPES, pH 7.8, 10 mM K-
EDTA, 5 mM ATP, 2 mM DTT and 2 mM PMSF in a Glass-Col
homogenizer (20 strokes at 70 setting). Homogenates were
centrifuged at 40,000 g at 4uC for 40 minutes. The salt
concentration of the supernatant (S-1) was raised to 0.6 M NaCl,
and the solution was incubated on ice for an hour followed by
centrifugation at 150,000 g for 2 hrs to isolate Myo Va enriched
pellet. The pellet (P-2) was suspended in a buffer (50 mM Tris/
HCl pH 7.5) and Myo Va-ATPase assay was carried out with
Novus Biological kit (Littleton, CO) according to manufactures
suggestions and an excess amount of purified actin (5 mg from
bovine skeletal muscle) or NF-L (10 mg, from mouse spinal cord)
was added in a separate assay.
Blot overlay assays
Blot overlay assays were conducted as described previously [16].
Briefly, purified vimentin (Cytoskeleton, Denver, CO), desmin
(Prospec, Rehovot, Israel), actin (Sigma, St. Louis, MO) or
recombinant or cytoskeletal preparations from brain, optic nerve,
spinal cord, and sciatic nerves were fractionated on 7% acrylamide
gels containing SDS. Proteins on these gels were transferred to
nitrocellulose membranes, blocked, incubated with MBP-tagged
Myo Va constructs overnight at 4uC, washed, incubated with a-
MBP-HRP antibody (New England Biolabs, MA) and washed.
Immunoreactive signals were detected with ECL reagent.
Morphometric analysis and density measurements for ER
Mice were perfused and optic nerves were fixed and embedded
for electron microscopy as described previously [16]. Sections
were taken at the 2-mm level of optic nerve, imaged, and
photographed at 25K magnification. ER profiles were counted
from axons of caliber sizes representative of the whole nerve using
Bioquant software (Nashville, TN). The total numbers of ER were
divided by the axon area to obtain the density of organelles in a
given axon. To analyze the peripheral distribution of ER vesicles,
cross sections of WT, NF-L null, DL20J and dilute lethal control
(DLC) optic axons were imaged at 25K and printed at 50K
magnification. ER vesicles that were within 100 nm from the
periphery of the axolemma were considered peripheral and those
more centrally located in the axon were considered non-
peripheral. Optic axons that were larger than 1 mm were taken
for analysis from WT (n=81), NF-L null (n=63), DLC (n=69)
and DL20J (n=100) mice.
Results
Myo Va binds to NF-L through its motor head domain
To identify which of the Myo Va mutants bind to full length
NF-L, we co-immunoprecipitated (co-IP) each of these Myo Va
mutant proteins (Fig. 1A and Fig. S1A-E) in equimolar quantities
with an excess of NF-L, using the antibodies NR-4 or 21.4 for
purified NF-L and 9E10 for Myc tagged NF-L (Fig. S1F). Analysis
of the immunoprecipitates (IPs) by Western blotting using MBP
antibody indicated that both the Myo Va head domain (5-752,
Fig. 1B, lane 7) and the neck region (760-922, Fig. 1B, lane 8)
bound to the NF-L subunit (Fig. 1B), while the tail region (Fig. 1B,
lane 9) failed to show binding activity under these conditions. Our
IP assays also demonstrated that the head region of Myo Va
bound to NF-L more than the neck domain (compare lane 7 with
8 in Fig. 1B). The latter construct was part of the very long Myo
Va construct (654-1402; see Fig. 1A) previously used to show
binding to NF-L [16].
The Myo Va cargo binding region is present in the tail region
where it binds to melanosomes [27]. The tail region of the Myo Va
(952-1852) construct, however, did not bind to NF-L in our co-IP
experiments (Fig. 1B lane 9). To exclude the possibility that
tagging the tail region with MBP interferes with its binding, we
tagged the tail constructs with hexa-His peptide at the N-terminus
of the various Myo Va mutants, and also divided the tail region
into 2 parts (952-1256 and 1257-1852 amino acids) (Fig. 1A & Fig.
S1E). Co-IP studies indicated that these tail mutants have no
binding activity with full-length NF- L whereas the Myo Va head
bound to NF-L in the same experiments (data not shown).
We confirmed the specificity of Myo Va head binding to NF-L,
by co-immunoprecipitating NF-L with either MBP-Myo Va-Head
Functions of NF-L and Myosin Va Binding
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Head did co-immunoprecipitate with NF-L, while MBP alone or
BSA (data not shown) showed no binding activity, indicating that
the MBP-Myo Va head interaction with NF-L is specific.
We next used spinal cord cytoskeletal fractions in blot overlay
assays [16] to confirm our IP studies and to investigate whether the
head and neck regions of Myo Va have similar binding affinities
towards NF-L. After SDS-PAGE, cytoskeletal proteins were
transferred to nitrocellulose membranes and subjected to blot
overlay assays with Myo Va head and neck regions at equimolar
ratios. The blot overlay results demonstrated that the Myo Va
head region showed more binding activity (Fig. 1C, lane 2) with
Figure 1. Schematic representation of Myo Va deletion constructs. (A). Amino acid numbers correspond to the mouse dilute gene product
[6]. The three domains of Myo Va are color coded (head-grey; rod-black and tail-white). The mutant proteins are either tagged with MBP (Hatched-
circle) or hexa-His-peptide (star) or 3-kDa b-gal peptide (hatched-triangle). Constructs 5–752, 760–922 and 899–1830 are from chicken [11]. The
construct tagged with b-gal-654-1402 is of human origin [15], and the tail clones originate from the mouse sequence [6]. Clones 718-799 and 800–
881 are PCR products from chicken Myo Va [11]. (B) Relative binding of Myo Va tail, head and neck regions to NF-L. Myo Va head, neck and tail domains
were incubated with NF-L, co-immunoprecipitated with NF-L antibody (NR-4), immunoprecipitates (IPs) and supernatants (Sup, 10%) were
immunoblotted with anti-MBP and NF-L antibody (NR-4) and immunoreactive bands were detected with ECL reagent. The molecular weight (MW) of
Myo Va head domain-120, neck-60 and tail is 140-kDa. *-indicates non-specific binding. (C) Myo Va head region shows more binding to NF-L
compared to the neck region in blot overlay assays. Cytoskeletal fractions from spinal cord fractionated on 7% acrylamide gels containing SDS,
transferred to nitrocellulose membranes, blocked with 3% milk, incubated with head and neck constructs tagged with MBP at equimolar
concentrations, immunoblotted with anti-MBP-HRP antibody and immunoreactive bands were detected with ECL reagent. Ponc. S: Pnoceau S. (D)
Myo Va head region binds to NF-L, a-internexin, peripherin and GFAP in blot overlay assays. Cytoskeletal fractions from optic nerve (ON), spinal cord
(SC), and sciatic nerve (SN) were fractionated, and the Myo Va head domain binding activity was detected by blot overlay assay as described in panel
C. (E) Myo Va head region binding to NF-L is specific since NF-L deficient cytoskeletal preparations do not show NF-L binding activity. Cytoskeletal
fractions from WT and NF-L null (NF-L KO) mice spinal cord (SC) and sciatic nerve (SN) were fractionated and blot overlay assays were performed to
detect Myo Va head domain binding activity as described in panel E. The positions of the bands on the membranes are indicated with arrows in all
panels. Anti-MBP: a-MBP; anti-NF-L:a-NF-L.
doi:10.1371/journal.pone.0017087.g001
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been previously shown to bind a part of a larger construct (954-
1402) [16].
In similar blot overlay analyses, we confirmed that NF-L is a
major ligand for the Myo Va head domain (5-752) in optic and
sciatic nerves and spinal cords of WT mice (Fig. 1D). Upon longer
exposure of the autoradiographs, however, we found that three
additional IF proteins, a-internexin, peripherin, and GFAP, also
bound to the Myo Va head in optic nerve (Fig. 1D, lane 1).
Moreover, Myo Va bound GFAP in spinal cord (Fig. 1D, lane 2),
and peripherin in sciatic nerves (Fig. 1D, lane 3). These results
suggest that Myo Va head binds to different neuronal IFs.
To further demonstrate the specificity of Myo Va head binding
to NF-L, we subjected cytoskeletal fractions of spinal cord
(Fig. 1E, lanes 1, 2) and sciatic nerves (Fig. 1E, lanes 3,4) from
WT (Fig. 1E, lanes 1, 3) and NF-L null (Fig. 1E, lanes 2, 4) mice
to blot overlay assays with the Myo Va head region. The results
revealed that spinal cord and sciatic nerve cytoskeletal fractions
from WT mice showed strong NF-L binding activity (Fig. 1E,
lanes 1, 3), while the same activity was absent in NF-L null mice
(Fig. 1E, lanes 2, 4). Moreover, both WT and mutant mouse
spinal cords showed GFAP binding activity with the Myo Va
head region (Fig. 1E, lanes 1, 2). These results suggest that the
interactions between Myo Va and NF-L are specific. It was
shown previously that loss of NF-L in sciatic nerves dramatically
reduces levels of axonal peripherin [28]. As expected, therefore,
we were unable to detect binding of Myo Va to peripherin in
sciatic nerves of NF-L null mice (Fig. 1E lane 4); however, the
binding of Myo Va to peripherin was readily detected in sciatic
nerve fractions of WT mice (Fig. 1E, lane 3).
In the above studies, the Myo Va head domain construct used
spans amino acids 5-752. We constructed 3 additional mutants of
the head region (41-505, 41-326 and 327-505), which were tagged
with MBP (Fig. 1A) to further define the NF-L binding site on this
region. Co-IPs at equimolar ratios with these Myo Va constructs
demonstrated that the 41-505 (Fig. 2A, lane 12) and 41-326
(Fig. 2A, lane 11) but not the 327-505 (Fig. 2A, lane 10) region of
Myo Va bound to NF-L. These results confirm that Myo Va binds
NF-L principally through the N-terminal region of the head
domain, which contains the ATP binding region and the motor
domain. To confirm the differential binding activities of these two
constructs seen in IP assays with NF-L, we subjected cytoskeletal
fractions from spinal cord to blot overlay assays with 41-326 and
327-505 in equimolar amounts. Only 41-326 bound to NF-L
(Fig. 2B, lane 2), whereas 327-505 failed to show binding activity
(Fig. 2B, lane 3) in spinal cord fractions.
Because our studies previously demonstrated binding activity of
a Myo Va construct containing the neck region (654-1402) [16],
we constructed three additional neck mutants (Fig. 1A). These
neck mutants were highly unstable, which made binding assays
with these constructs very difficult to perform. Additional co-IPs to
investigate the relative binding activity of head and neck constructs
revealed that the Myo Va head region (41-505) bound to NF-L
under conditions where 800-881 showed much less binding
activity (Fig. 2C, compare lanes 3&4). The quantitative data from
multiple experiments demonstrate that the Myo Va motor domain
(41-505) showed significantly more binding activity compared to
the 800-881 construct (Fig. 2D, p,0.015). Additional blot overlay
assays also demonstrated that, at equimolar concentrations, the
41-505 construct showed more binding activity to NF-L (Fig. 2E,
lanes 3,4) compared to 800-881 fragment (Fig. 2E, lanes 5&6) in
spinal cord (Fig. 2E, lanes 1, 3 and 5) and sciatic nerve (Fig. 2E,
lanes 2, 4 and 6) fractions.
Myo Va motor domain binds to the amino terminal end
of the NF-L rod domain
To identify the site on NF-L to which the Myo Va motor
domain binds, we constructed four Myc-tagged NF-L deletion
mutants (1-369; 1-243; 1-93 and 94-243; Fig. 3A) by restriction
enzyme digestion (see Methods). The physical properties of NF-L
deletion constructs are described in Table 1. The molecular
weights of these constructs measured on SDS-PAGE differ from
the calculated molecular weights due to abnormal behavior of NF
proteins on these gels [29]. The WT NF-L displayed pI values of
4-5 in the acidic range while the head domain has a basic pI of 9.8.
The full length NF-L and the mutants were detected with anti-
Myc antibodies (Fig. S1G).
To test which of the NF-L deletion construct would bind to the
Myo Va motor domain (41-326), we performed co-IP assays. Our
data indicate that Myo Va bound to all the NF-L constructs
containing amino acids 94-243 in the rod domain (Fig. 3B, lanes
2–4). By contrast, construct 1-93 containing the head domain of
NF-L, showed negligible binding to the Myo Va motor domain
(Fig. 3B, lane 5). Therefore, our data, identify the Myo Va binding
site on NF-L as the N-terminal portion of the rod domain
encompassing amino acids 94–243. The binding of Myo Va to
cellular cargoes is regulated by calcium and magnesium in the cell
[30]. We tested whether these ions would modulate the Myo Va
motor domain (41–326) binding to NF-L. Our co-IP studies in the
presence of these ions indicate that Mg
2+ enhanced binding
(Fig. 3C, and the graph in C) while Ca
2+ had an insignificant effect
on Myo Va-NF-L binding (Fig. 3C, lanes 4, 5).
Myo Va motor domain binds to multiple intermediate
filaments
All IF proteins have a common structural core of 300–330 amino
acid residues within the rod domain, which are flanked by variable
amino- and carboxy-terminal regions [31]. To investigate possible
binding of other IF family members to Myo Va motor domain, we
performed blot overlay assays with the IF preparations made from
mouse brain, sciatic nerve, spinal cord, purified NF-L, actin (bovine
skeletal muscle), vimentin (hamster), desmin (human), and keratin
fromhumanskin.Ourdataindicatethatthe MyoVamotordomain
not only binds to NF-L from brain, sciatic nerve, spinal cord and
purified NF-L from mouse spinal cord as a major ligand (Fig. 3D,
lanes 1–4) but also binds to GFAP (Fig. 3D, lanes 1,3), a-internexin
(Fig. 3D, lane 3), peripherin (Fig. 3D, lane 2), vimentin (Fig. 3D,
lane 6) and desmin (Fig. 3D, lane 7), but not to actin or keratin
(Fig. 3D, lanes 5,8). As expected, actin (Fig. 3D, lane 5) did not bind
to this Myo Va construct (41–326) because the construct lacks the
binding site for actin (amino acids 643–666) [32].
F-actin activates Myo Va-ATPase activity while NF-L does
not
The actin and NF-L binding sites are about 300 amino acids
apart on the Myo Va head domain (Fig. 3E). Because of this
proximity, it is possible that NF-L and actin may compete with
each other to bind to Myo Va; however, the Myo Va head
construct, containing the actin binding site, did not bind to actin
despite attempts using various conditions. Actin has previously
been observed not to bind to the bacterially expressed full length
Myo Va head protein because it does not fold properly, which is
necessary for its actin binding activity (Mark Mooseker, personal
communication). Our published data indicate that under in vivo
conditions, Myo Va, NF-L and actin holoproteins form complexes
and these were identified by co-immunoprecipitation assays in
mouse optic axons [16].
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would activate Myo Va-ATPase activity, we incubated fraction-
ated Myo Va (P2 fraction, [26]) with NF-L in an ATPase assay
buffer. We did not find an increase in Myo Va-ATPase activity
with addition of NF-L, while addition of F-actin led to an increase
in Myo Va-ATPase activity in a parallel assay. These data indicate
that NF-L binding to Myo Va, by itself, does not activate Myo Va-
ATPase activity in our assay conditions (Fig. 3F).
Loss of NF-L and NF-networks in axon leads to reduced
scaffold function and lowered axonal organelle content
IFs serve as cytoskeletal scaffolds in the nucleus and cytoplasm
of higher metazoans [33,34]. Myo Va binds to synaptic vesicles,
ER, Golgi, endosomes and mitochondria [16,35], and also to the
NF-L subunit. Loss of NF-L leads to reduced Myo Va in axons
[16]. We hypothesized that if the cellular organelles are anchored
within axonal NF networks through Myo Va to stabilize their
positions in the axon, then loss of Myo Va-NF-L interactions
would be expected to reduce organelle associations with NF
scaffolds and lead to reduced organelle content as organelles
resume axonal transport ultimately back to the perikaryon for
degradation. To test this hypothesis, we homogenized the optic
nerves of NF-L null mice in an isotonic 0.25 M sucrose buffer, and
centrifuged at low speed (7000 g) to isolate the organelles that
associate with NF-networks under isotonic conditions. As predict-
ed, a major proportion of organelles analysed (ER, synaptic
vesicles, endosomes) fractionated into the cytoskeletal fraction,
including the majority of calnexin (a marker of ER), Rab-5 and
Rho B (endosomal markers), and synaptophysin (SYP, a synaptic
vesicle marker) (Fig. 4A-F), implying either direct associations
between NFs and vesicular structures (ER, synaptic vesicles,
endosomes) or entrapment of these organelles within the NF
Figure 2. Myo Va motor domain binds to NF-L. (A) The N-terminal motor domain (41–326) of Myo Va binds to NF-L in co-IPs. Myo Va head
domain (41–505), N-terminal head domain (41–326), C-terminal head domain (327–505) proteins were incubated with or without NF-L and
immunoprecipitated with NF-L antibody (NR-4), IPs and Sups (10%) were immunoblotted with anti-MBP-HRP, and anti-NF-L antibody (NR-4). The
immunoreactive bands were detected as described in Fig. 1B. Myo Va head domain (41–505) is 95-kDa, 41-326 is 75-kDa and 327–505 is 52-kDa. (B)
The N-terminal domain of Myo Va (41–326) binds to NF-L in blot overlay assays at equimolar concentrations with spinal cord cytoskeletal fractions.
Lane 1 Ponceau S stain (Ponc. S.) of SC cytoskeletal fraction, SC cytoskeletal fractions in lane 2 and 3 were incubated with 41–326 and 327–505 of Myo
Va head mutants and blot overlay assays were performed as described in Fig. 1C. (C&D) Myo Va head domain (41–505) shows significantly more
binding to NF-L in co-IPs (C&D, *-p,0.011) and blot overlay assays (E) compared to neck region (800–881). The MW of 800–881 is 50-kDa. Error bars
represent SEM. Myo Va head domain (41–505) and neck region (800–881) were separately incubated with or without NF-L and immunoprecipitated
with NF-L antibody (NR-4). IPs and Sups (10%) were immunoblotted with MBP-HRP and NF-L antibodies in panel D. (E) Cytoskeletal fractions from
spinal cord (SC, Fig. 2E, lanes 1, 3&5) and sciatic nerves (SN, Fig. 2E, lanes 2, 4&6) of WT mice were transferred to nitrocellulose membranes and
Ponceau S stained (Fig. 2E, lanes 1&2), and blot overlay assays were performed with Myo Va head (41–505, lanes 3&4) and neck regions (800–881,
lanes 5&6) at equimolar concentrations. The positions of proteins in all membranes were indicated with an arrow. Anti-MBP: a-MBP; anti-NF-L:a-NF-L.
doi:10.1371/journal.pone.0017087.g002
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PLoS ONE | www.plosone.org 6 February 2011 | Volume 6 | Issue 2 | e17087Figure 3. The N-terminal rod domain of NF-L binds to the motor domain of Myo Va. (A) Schematic representation of NF-L subunit domains
and the deletions. Amino acids are numbered according to [31]. See materials and methods for construction of NF-L domain deletions. B. The amino-
terminal motor domain of Myo Va (41–326) binds to the N-terminal rod domain of NF-L. Myo Va constructs were MBP-tagged while NF-L was myc-
tagged. Co-immunoprecipitation of NF-L deletion constructs with Myo Va motor domain (41–326). Myo Va was incubated without NF-L (lane 1), with
full length NF-L 1-543 (lane 2); NF-L 1-243 (lane 3); NF-L 94-243 (lane 4) and NF-L 1-93 (lane 5) were immunoprecipitated with Myc antibody (9E10), IPs
and Sups (10%) were immunoblotted with anti-MBP or anti-Myc antibodies. The molecular weights of NF-L 1-543, 1-243, 94-243 and 1-93 are 68, 27,
20 and 17-kDa respectively. (C) Magnesium ions potentiate Myo Va and NF-L binding. Myo Va motor domain (41–326) was incubated with NF-L (Full
length) and immunoprecipitated with a-Myc antibody. The resulting IPs and 5% of sups were immunoblotted with a-MBP-HRP or a-Myc Abs.
Addition of magnesium (5 mM) increased binding (see the graph in 3C) while addition of magnesium and calcium (5 mM) further increased the
binding of NF-L to Myo Va (compare lane 6 with 5 and 7). Arrows indicate the position of Myo Va motor domain (41–326) of 75-kDa protein. The *-
indicates proteolytic fragments of 41–326 construct generated with incubation of calcium and magnesium in both IP and supernatant fractions in
lanes 4&5 while these are seen only in IP fractions of lanes 6&7. (D). Myo Va head domain binds to different IF family members. Cytoskeletal
preparations from brain (lane 1), sciatic nerve (lane 2), spinal cord (lane 3), purified NF-L (lane 4), purified actin (lane 5), purified vimentin (lane 6),
purified desmin (lane 7) and fractionated keratin from human skin (lane 8) were separated on gels and transferred to membranes. Blot overlay assays
were performed on membranes with MBP-Myo Va (41–326) protein and immunoblotted with a-MBP-HRP antibody. Anti-MBP: a-MBP; anti-NF-L: a-NF-
L and anti-myc: a-myc. (E) Schematic representation of NF-L and Actin binding sites on Myo Va head domain (1-752). The amino acids are numbered
according to [6]. (F). Actin activates Myo Va-ATPase activity while NF-L does not. Myo Va was fractionated from adult mouse brain according to [26] (P2
fraction enriched in vesicular Myo Va) and incubated with either actin or NF-L and assayed for ATPase activity. Addition of actin to P2 fraction
activated Myo Va-ATPase activity while addition of NF-L did not. *p,0.02. Error bars represent SEM in all experiments.
doi:10.1371/journal.pone.0017087.g003
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Rho B, calnexin, and SYP were significantly lowered compared to
the cytoskeletal fractions from WT mice (Fig. 4A-F). However, the
content of actin, tubulin and PSD-95 between WT and NF-L null
axons was not significantly altered (Fig. 4G-I). The reduced
content of calnexin, Rab-5, Rho B and SYP in total homogenates
of NF-L null optic extracts is most consistent with a failure to
anchor organelles in the axon and with their ultimate retrograde
transport back to the perikarya for degradation (data not shown).
Loss of Myo Va also reduces organelle markers in dilute
lethal (DL20J) optic axons
Myo Va associates with NFs, and loss of NFs leads to a 50%
reduction in axonal Myo Va (16) in NF-L null optic axons.
Moreover, Myo Va is involved in the transport of synaptic vesicles,
ER, and other membrane-bound organelles [35]. We tested the
possibility that loss of Myo Va also would lead to reductions in
organelle markers similar to those observed for NF-L null axons
(Fig. 4A-F). Our immunoblot analyses of optic nerve extracts from
the Myo Va mutant (DL20J) mice demonstrate that calnexin and
synaptophysin (SYP) were significantly reduced compared to
littermate dilute lethal control (DLC) axons (p,0.05) (Fig. 4J-L),
but actin, a-tubulin, and PSD-95 were not altered (Fig. 4M-O).
Loss of NF-L or Myo Va leads to reduced content and
peripheral distribution of ER vesicles in the axon
If NF-L-Myo Va binding cage and/or anchor organelles to
maintain a relatively uniform organelle distribution throughout the
axoplasm, we hypothesized that loss of the NF-L or Myo Va would
reduce the content of organelles and possibly alter their distribution
within NF-L and Myo Va mutant axons. To test this possibility, we
performed electron microscopy of fixed optic axons of NF-L null
and DL20J mice, and further morphometric analysis by counting
clear ER vesicles in these mutant axons and calculating the density
of ER (see methods). Our morphometric analysis of NF-L null or
DL20J optic axons demonstrated significantly lower numbers of
smooth ER, compared to controls (Fig. 4P).
Moreover, we observed that clear vesicular organelles normally
distribute uniformly throughout the three-dimensional space of
axons in WT mice (Fig. 5A, C, E, F). Consistent with the
predominant association of ER and endosome markers with the
NF cytoskeleton (Fig. 4), the organelles (ER, endosomes and
mitochondria) were frequently flanked on both sides by NFs,
which seemed to contact the organelles, or even enclose the
vesicular structures, as described previously for melanosomes
caged by vimentin filaments in non-neuronal cells [36]. By
contrast, in NF-L null optic axons, these organelles were
redistributed to the periphery of the axon and lined up in
channels in the subaxolemmal area (Fig. 5B, G). We also observed
a similar redistribution of ER, endosomes and mitochondrial
profiles in DL20J optic axons (Fig. 5D) compared to DLC axons
(Fig. 5C). Our morphometric quantitative measurements con-
firmed the redistributions identified by visual inspection (Fig. 5H,
I). ER located within 100 nm from the axolemma was scored as
having a peripheral distribution. Organelles more centrally located
were scored as non-peripheral. Our data on cross-sectioned axons
(.1 mm) from WT (n=81), NF-L null (n=63), DLC (n=69), and
DL20J (n=100) mice demonstrated a significant redistribution of
ER toward the periphery of axons in NF-L null (Fig. 5H) and
DL20J mice (Fig. 5I) compared to their controls, while total axonal
content was lowered similarly in NF-L null and DL20J mice
(Fig. 4P). The effect on the peripheral distribution of ER in Myo
Va mutant axons was less prominent though similar compared to
that in NF-L null axons.
Loss of NF-L does not alter synthesis or translocation
rates of radiolabeled proteins that contain ER vesicles
undergoing fast axonal transport in vivo
To investigate whether reduced axonal Myo Va levels in NF-L
null mice [16] would alter export and fast axonal transport of
membranous organelles (ER, endosomes, synaptosomes) along
optic axons, we analyzed the export, transport rates, and
composition of cargoes (SNAP-25, p85, and p135) that are known
to translocate at fast transport rates after injecting NF-L-null mice
intravitreously with [
35S]-methionine as previously described [37].
Our data indicate that the export of SNAP-25 (synaptosome
marker), p85 and p135 and the rates of fast transport of SNAP-25,
p85 and p135 were not significantly altered in the absence of NF-L
(data not shown), where there is a 50% reduction of axonal Myo
Va [16]. The distribution patterns of radiolabeled actin and
tubulin proteins were also unaltered in NF-L null axons (data not
shown). For both NF-L null mice and age-matched controls, peak
and front wave rates were 12 and .38.4 mm/day, respectively,
for p135, 16.8 and .38.4 mm/day for SNAP-25, and 12 and
.21.6 mm/day for p85 consistent with previous rate estimates
[37]. These results suggest that NF-L does not contribute to the
export and the transport rates of fast axonal transport cargoes in
optic axons.
Discussion
Our studies identify a novel role for the binding between Myo
Va and NFs as a mechanism to anchor organelles within the
Table 1. Some Physiochemical Properties of Engineered NF-L Constructs.
NF-L Source Amino acids
Observed Molecular
Weight
Calculated Molecular
Weight Protein Characteristics
Estimated
Pl
Acidic
AA %
Basic
AA %
Full length Mouse 1–543 68-kDa 68000 4.41 22.7 14.4
Headless Rat 65–543 54-kDa 61500 4.31 25.2 14.5
Tailless Mouse 1–369 37-kDa 47000 5 17.9 15.7
Head + Rod Mouse 1–243 27-kDa 28000 5 17.3 15.2
Rod Mouse 94–243 20-kDa 20000 4.5 24 16.7
Head Mouse 1–93 17-kDa 16000 9.8 6.46 12.9
doi:10.1371/journal.pone.0017087.t001
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specifically the NF-L rod domain, binds directly the N-terminal
motor domain of Myo Va. It is well-established that the MyoVa
cargo domain binds vesicular organelles (7–9), and our morpho-
logical and fractionation data (this study and [16]) demonstrate
associations among vesicular organelles, Myo Va, and NF-L. We
showed that NF-L loss reduced axonal levels of both Myo Va and
organelles and increased peripheral distribution of ER toward the
actin-rich subaxolemmal region. Consistent with these findings,
loss of Myo Va in DL20J mice similarly reduces axonal organelle
number and also increases peripheral distribution of ER.
It is known that NFs in large caliber axons are organized into an
extensively cross-linked network containing microtubules, and
actin filaments through multiple cross- bridging proteins [38,39].
NFs in mature axons form a highly metabolically stable stationary
network maintained by a smaller pool of newly synthesized
subunits continuously transported along axons in the form of
dimers, oligomers, or short filaments [40]. Video microscopy
analyses of axons in vitro show that subtypes of vesicular organelles
display different kinetic behaviors ranging from very rapid,
relatively continuous anterograde and retrograde movements that
span long distances to infrequent short range bidirectional
movements separated by short or very long pauses [41,42]. It is
possible that NF networks form scaffolds for retaining these
organelles and organizing their topography locally within axons.
Several lines of evidence from our studies indicate that Myo Va
binding to NF-L regulates organelle distribution in the axon but
loss of this interaction does not affect the slow or fast axonal
transport cargoes ([16] and this study). However, Myo Va is
implicated in the transport of neurofilaments and has been
suggested to be involved in translocations of fast transport
vesicular cargoes [7,35,43,44]. We observed that Myo Va binds
NF-L through its motor domain rather than its cargo domain (tail),
making it unlikely that NFs are Myo Va cargoes. Long range Myo
Va-mediated movements on NFs were also unlikely in light of our
observations that NF-L deletion had no effect on the fast transport
of vesicular organelles in vivo or in vitro (Rao et al., unpublished
observations). Our previous studies also demonstrated that
depletion of NFs and axonal Myo Va had no effect on slow
axonal transport rates of NF-M or actin [16,17]. However, the
presence of NFs in the axon slows the rate of transport of Myo Va
[16], presumably by the intermittent binding of Myo Va to NF-L
within stationary NF networks in the axon.
An important role of NFs in maintaining the normal local three-
dimensional organization of vesicular organelles in optic axons is
suggested by our study. Membranous organelles were often seen
closely opposed to NFs, which frequently flanked or surrounded
the organelle, similar to that described for vimentin filaments and
lysosomal compartments in non-neuronal cells [45]. In addition, a
greater abundance of protein markers for vesicular organelles co-
isolated with the cytoskeleton in optic fractions from NF-rich WT
mice than from NF-L null mice. Moreover, loss of NF-L promoted
the peripheral redistribution of organelles (this study) and Myo Va
[16]. In further support for an organelle-anchoring role of NFs, we
observed substantially reduced numbers of ER vesicles in axons of
NF-L null mice despite the absence of detectable effects on fast
Figure 4. NF-network-dependent association of cellular organ-
elles is reduced in NF-L null optic axons. Cytoskeletal (lanes 1&2),
and supernatant fractions (lanes 3&4) from WT (lanes 1&3) and NF-L null
(lanes 2&4) optic nerves were resolved by SDS-PAGE, transferred to
membranes, Ponceau S stained (A), immunoblotted with NF-L (B), Rab-5
(C), Rho B (D), calnexin (E), Synaptophysin (SYP, F), actin (G), tubulin (H),
and PSD-95 (I) antibodies. Densitometric quantification of signals from
immunoblots in panels C-F indicate significantly reduced amounts of
Rab-5 (C), Rho B (D), calnexin (E), Synaptophysin (SYP, F), in NF-L null
cytoskeletal fractions compared to controls while actin (G), tubulin (H),
and PSD-95 (I) were not decreased in the same fractions. (n=6 for each
genotype of 5–6 month old mice). (J). Total extracts of optic nerves
from DLC (dilute lethal control), and DL20J mice were immunoblotted
with Myo Va, calnexin, Synaptophysin (SYP), actin, tubulin and PSD-95
antibodies. Quantitation data for calnexin (K), synaptophysin (SYP; L),
PSD-95, actin and tubulin is shown in M-O. (P). Morphometric analysis
indicate reduced density of ER vesicles in NF-L null and DL20J optic
axons (n=4 for 5–6 month old WT and NF-L null, and 17 day for DL20J
and DLC). *p,0.05, and **p,0.01. Error bars represent SEM in all
experiments.
doi:10.1371/journal.pone.0017087.g004
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transport cargoes into axons. The absence of detectable transport
changes despite decreases in organelle number in axons is not
unexpected if, as observed, anchored organelles are stationary for
long periods relative to their rapid movement when they are ‘‘on
track’’. Very small changes in the drop off rate of vesicles from the
transport track into a relatively stationary pool could result in
substantial reduction in the size of this pool over time without
detectably altering the rate of fast transport. Because a-internexin
levels are maintained in NF-L KO optic axons [46] despite
marked declines in NF-M and NF-H, it is also possible that a-
internexin could have compensatory effects on transport. The
influence of NF-L on ER and endosome content and organization
is not a non-selective effect on vesicular transport or general
mechanisms regulating organelles in axons because the density of
mitochondria and levels of axonal mitochondrial protein cyto-
chrome C are increased in NF-L null optic axons (Rao et al.,
unpublished results). Similar increases in mitochondria and their
protein markers have also been observed in desmin null mice and
in cells where the vimentin cytoskeleton is disrupted [47,48].
Bacterially expressed NF-L and Myo Va fusion proteins that are
deficient in post-translational modifications such as phosphoryla-
tion and glycosylation bound each other directly without an
adaptor protein in our in vitro binding studies. This observation
implies that posttranslational modifications do not regulate the
association between these two proteins. Our observation that
Mg2+ enhances the Myo Va and NF-L interaction raises a
possibility that changes in levels of these ions may regulate the
binding activity between these two proteins. A similar mechanism
has been proposed for the regulation of interaction between Myo
Va and Syntaxin-1A [30].
Our studies identify the NF-L rod domain as the Myo Va
binding site that forms the backbone of NFs, The abundance of
NF-L subunits in the NFs (4:2:2:1 stoichiometry with NF-M, a-
internexin and NF-H) [17] and the putative heptad arrangement
of rod domains forming the NF core represents a continuous linear
array of Myo Va binding sites along axons suitable for organelle
attachment through Myo Va. Moreover, as axons expand in
caliber, the growth of the actin cytoskeleton does not keep pace
with increases in axonal volume and NF networks. This
circumstance leads to markedly lower ratios of actin filaments to
NFs in large caliber axons compared to smaller ones [49]. Our
immunogold data on axons showing the actin network to be
discontinuous (Rao et al., unpublished observations) suggests that
its networking with both microtubules and NFs might provide the
continuity needed for distributing organelles radially and longitu-
dinally and retrieving them for movement on actin or microtu-
bules to a new location. In this regard, recent evidence suggests
that myosin, kinesin, and dynein motor systems can transport the
same cargo on either actin or microtubule based platforms [50]. It
is also proposed that Myo Va diffuses through actin and
microtubule intersections to transport cellular organelles [50,51].
However, one study suggests that changing the track for Myo Va
from actin to microtubules happens directly without diffusion [52].
Figure 5. Loss of NF-L and Myo Va leads to increased
peripheral distribution of ER vesicles in optic axons. In cross
sections of WT (A), and dilute lethal control (DLC) (C) axons a clear
tubulo-vesicular and vesicular profiles distribute diffusely in the radial
dimension (A&C) but are more peripherally distributed in NF-L null (B)
and DL20J (D) optic axons (see arrows in A–D). In comparison to WT
axons (E, F, see arrows), cellular organelles in NF-L null optic axons (G)
are peripherally distributed along channels beneath the axolemma in
longitudinal sections (see the arrows in G). Quantitative measurements
of distribution of organelles within 100 nm from periphery of axons
that are larger than 1 mm demonstrate that increased peripheral
distribution of ER in both NF-L null (H) and DL20J (I). (n=5 animals for
6-month old WT and NF-L null, and 17 day DL20J and DLC). **p,0.01,
and ***p,0.001. Error bars represent SEM. NF: neurofilaments; MT:
microtubules; Mito: mitochondria; Peri: peripheral; Non-peri: non-
peripheral.
doi:10.1371/journal.pone.0017087.g005
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of organelles from NFs to actin filaments or microtubules by Myo
Va (Fig. 6). Although ATPase activity of Myo Va is not required
for binding to NF-L, the binding of Myo Va to NF-L through its
motor domain raises the possibility that Myo Va may be able to
distribute cargoes along the NF.
Our studies confirm and extend our previous observations that
Myo Va binds selectively not only to NF-L but also to other IF
proteins of several classes, including a-internexin, GFAP, periph-
erin, vimentin, and desmin, but not keratin. A Blast analysis of the
IF proteins identified a highly conserved (EREGLEETLRNL)
sequence within the rod domain of IF proteins that bind Myo Va
(NF-L, vimentin, peripherin, desmin, a-internexin, and GFAP)
compared to IFs that do not bind Myo Va (NF-M, NF-H and
keratin). These observations suggest that IF networks may serve as
linear arrays for Myo Va-mediated organelle distribution in a
variety of cell types. In this regard, dynamic rearrangements of
vimentin have been shown to be important in modulating the
centrifugal movements of melanosomes in B16 cells [36]. Myo Va
mediated melanosome transport studies in Xenopus melanophores
indicate that IFs significantly slow down the run lengths of the
motor on microtubules. This particular study suggests that IFs
hinder Myo Va dependent organelle transport in melanophores
[52] and may thereby contribute to the three-dimensional
positioning of these organelles in the cytoplasm.
Supporting Information
Figure S1 Immunoblot analyses of Myo Va and NF-L
constructs. Bacterially expressed Myo Va head (5-752, 120-
kDa), neck (760-922, 60-kDa) and tail domains (899-1830, 140-
kDa) Coomassie stained (A) and immunoblotted with anti-MBP
antibody (B). Myosin Va head region of Myo Va was further
deleted to make 41-505 (95-kDa), 41-326 (75-kDa), and 327-505
(52-kDa) constructs (C), and the neck mutants 800-881 (50-kDa),
604-881 (85-kDa), 717-799 (65-kDa) (D) were immunoblotted with
MBP antibody. His-tagged tail domain deletion mutants (952-
1852, 120-kDa; 952-1256, 45-kDa and 1257-1852, 62-kDa) were
immunoblotted with hexa-His antibody (Fig. 1SE). (F) Purified
(lanes 1, 3, 5&7), and bacterially expressed (lanes 2, 4, 6&8) Myc
tagged NF-L (Coomassie stained, lanes 1&2), immunoblotted with
NF-L specific (NR-4, lanes 3&4, and 21.4, lanes 5&6) and anti-
Myc (9E10) antibodies (lanes 7&8). (G). Bacterial expression of
Myc-tagged NF-L mutants. Lane 1: full length NF-L (1-543, 68-
kDa); lane 2: C-terminal deletion mutant 1-369 (37-kDa); lane 3:
1-243 (27-kDa); lane 4: N-terminal rod domain 94-243 (20-kDa),
and lane 5: 1-93 (17-kDa) were immunoblotted with anti-Myc
antibody. The positions of the protein bands on all membranes are
indicated with arrows.
(TIF)
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Figure 6. A model depicting NF-mediated anchoring and movement of organelles via Myo Va. Tethering of ER, endosomes (En), and
other related vesicles to NFs are mediated by Myo Va to maintain normal abundance and distribution of these organelles in the axoplasm. The
abundance of NFs in large caliber axons and their intercalation with actin and microtubule systems provides a physical continuity that may facilitate
local distribution of organelles along these different filament systems via Myo Va. Loss of Myo Va-NF-L interaction in axons leads to reduced
abundance of organelles as they resume transport and are ultimately turned over in the cell body.
doi:10.1371/journal.pone.0017087.g006
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